: iStockAnalyst.com Symbols Feed

Briefs: SPNGE, PPHM

Tue, 20 Oct 2009 14:26:49 GMT

SPNGE.ob: Shares of SpongeTech traded down on Monday after trading resumed without the filing of new financial reports. It's been my opinion that even while the stock is not trading, sales are still ongoing and chances are that the stock could recover if sales were continuing at or near the same pace as they were before the recent turmoil. My opinion also comes with the assumption that the re-stated financial reports are not too far off from where they were previously.[More...]

Small-Cap Stocks Battling Brain Cancer

Tue, 08 Sep 2009 00:02:23 GMT

Each year nearly 20,000 people in the U.S. are diagnosed with primary brain cancers (with a similar number in Europe), according to NCI/NIH statistics, with Schering-Plough's (NYSE:SGP) Temodar (temozolomide or TMZ is classified as a DNA-methylating chemotherapy drug) given to nearly every patient with a diagnosis of GBM (the most common and aggressive form of brain cancer).[More...]

FDA, Clinical Trial Updates: JNJ, INCY, MEDX, CYTX, AGN, PPHM

Fri, 29 May 2009 12:08:55 GMT

Below is a summary of updates to the BioMedReports.com database of over 200 entries included in the FDA and Clinical Trial Calendars. The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline dates while the Clinical Trial Calendar encompasses pending clinical trial results (with a focus on late-stage, Phase 3 trials), pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, s (...)[More...]

First Rally Attempt

Tue, 15 Apr 2008 14:37:23 GMT

Good morning. Premarket futures have a positive bias following the PPI which rose +1.1% month over month and a better than expected Empire Manufacturing report.[More...]

Peregrine Pharmaceuticals Posts Q3 Loss

Thu, 12 Mar 2009 11:34:18 GMT

California-based biopharmaceutical company Peregrine Pharmaceuticals has reported consolidated net loss of $3.33 million, or $0.01 per diluted share for the third quarter of fiscal 2009 compared to consolidated net loss of $6.15 million, or $0.03 per diluted share for the same period of fiscal 2008.[More...]

Peregrine Pharmaceuticals to Report First Quarter FY 2010 Financial Results

Thu, 27 Aug 2009 11:56:00 GMT

Peregrine Pharmaceuticals, Inc. today announced that it will release its financial results for the first quarter of fiscal year 2010 on September 3, 2009 at 7:00 a.m. EDT and will host a conference call and webcast to discuss the results at 11:30 a.m. EDT on the same day.[More...]

NIAID Awards New Grant to Expand Studies of Peregrine's Anti-PS Antibodies to Treat Viral Hemorrhagic Fevers

Wed, 26 Aug 2009 11:56:00 GMT

Peregrine Pharmaceuticals, Inc. today announced that the U.S. National Institute of Allergy and Infectious Diseases has awarded a two-year, $763,000 grant to Philip Thorpe, Ph.D., of the University of Texas Southwestern Medical Center for research expanding its studies of anti-phosphatidylserine antibodies as potential treatments for viral hemorrhagic fever infections. Anti-PS antibodies work through a unique mechanism that allows the body's own immune system to recognize and attack virus infections. Previously published preclinical data and ongoing research support the potential of anti-PS antibodies for the treatment of VHF infections. The objective of the newly funded research is to evaluate a panel of new fully human anti-PS antibodies with different binding and functional properties as potential second-generation treatments.[More...]

Peregrine Pharmaceuticals to Present at the Jesup & Lamont 2009 Growth Stock & National Sales Conference

Thu, 23 Jul 2009 11:57:00 GMT

Peregrine Pharmaceuticals, Inc. today announced that senior management will present at the Jesup & Lamont 2009 Growth Stock & National Sales Conference on Thursday, July 30, 2009 at 8:30 am EDT at the Boca Raton Resort & Club in Florida.More information about the conference can be found at www.jesuplamontconferences.com. About Peregrine PharmaceuticalsPeregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara. Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. , which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com. Contacts:[More...]

Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech

Wed, 22 Jul 2009 12:58:00 GMT

Peregrine Pharmaceuticals, Inc. and Affitech A/S today announced that they have entered into a licensing agreement for antibody therapeutic rights under Peregrine's preclinical anti-VEGF antibody program. Under the terms of the agreement, Affitech will license exclusive worldwide rights to develop and commercialize products under Peregrine's selective anti-VEGF intellectual property portfolio, including the fully human antibody r84, which was discovered by Affitech and jointly developed by the companies under an ongoing collaboration. Under the license agreement, Affitech will be responsible for future preclinical and clinical development and potential product commercialization. Peregrine will receive an upfront payment, research fees and future milestone payments potentially totaling in the double-digit millions . Peregrine will also receive royalties on any future sales and a share of sublicensing revenues. Additional financial terms were not disclosed. Announcing the transaction, Steven W. King, president and CEO of Peregrine, said, 'This licensing agreement with Affitech is an excellent opportunity for both companies. The selective anti-VEGF antibodies we have been jointly developing with Affitech hold significant clinical promise and we are pleased that Affitech will now have the opportunity to develop and commercialize them on behalf of both companies. This agreement will allow us to realize positive short-term cash flow and at the same time maintain an interest in the significant upside potential of the anti-VEGF program. This agreement fits very nicely with our announced corporate strategy to monetize and advance our preclinical pipeline through partnerships or licensing agreements, while focusing our R&D efforts on advancing our later-stage clinical programs highlighted by our bavituximab Phase II cancer program, which is already generating promising clinical data.'Commenting on the licensing agreement, Dr. Achim Kaufhold, chief executive officer of Affitech, said, 'Using advanced phage display technologies, Affitech successfully identified fully human, potent and selective anti-VEGF antibodies as part of a previous research and development collaboration with Peregrine. As a result of the recently completed reverse acquisition of Pharmexa, Affitech has now added product development expertise to its drug discovery capabilities. We are therefore delighted now to have acquired the exclusive worldwide development and commercialization rights for this exciting program.' Anti-VEGF therapy has become a standard part of treatments for many different types of solid tumors. According to projections of some market analysts, sales of anti-VEGF antibodies are expected to exceed $10 billion by 2015. The fully human and selective anti-VEGF monoclonal antibody, r84, which is the most advanced candidate in Peregrine's anti-VEGF antibody program, targets the cancer-promoting growth factor VEGF. Data presented at IBC's 5th Annual International Anti-Angiogenesis Conference in 2007 showed that r84 was as effective as Avastin in inhibiting tumor growth in a number of models of human cancers, including a mouse model of human breast cancer. r84 is distinctive because it selectively blocks VEGF from binding to VEGF receptor 2 , while non-selective agents such as Avastin block binding to both VEGFR2 and VEGF receptor 1 . Selective anti-VEGF agents such as r84 may have safety and efficacy advantages over non-selective approaches. In addition, the fully human nature of the r84 antibody minimizes the risk of an immune response against the drug itself, thereby lessening the potential for immunological side effects and neutralization of the treatment effect. As a fully human antibody, r84 may also have better pharmacokinetic properties in patients.About Affitech A/SAffitech A/S is an antibody research and development company. It was formed recently by a reverse merger of Norway, Oslo-based Affitech AS with Pharmexa A/S, a Danish biotech company. The merged company has developed several proprietary technology platforms that constitute a highly productive, fully human, antibody discovery engine. Based on its proprietary technologies and know-how, Affitech has built a pipeline of promising human antibody candidates for internal development or co-development with collaboration partners. The focus of the newly expanded company is to pursue both research and clinical development of antibody therapeutic products. Further information can be found at www.affitech.com.About Peregrine PharmaceuticalsPeregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara. Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. , which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that the company will not receive some or all of the future milestone payments or royalties, the risk that the program does not have significant upside potential and the risk that sales of anti-VEGF antibodies do not achieve the levels projected by some market analysts. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2009. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release Contacts:[More...]

Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009

Tue, 14 Jul 2009 10:57:00 GMT

Peregrine Pharmaceuticals, Inc. , today announced financial results for the fourth quarter and fiscal year 2009 ended April 30, 2009. Total revenues for the fourth quarter of FY 2009 increased to $7,867,000, compared to $901,000 for the comparable quarter in FY 2008. Total revenues for the 2009 fiscal year increased approximately 200% from $6,093,000 in FY 2008 to $18,151,000 in FY 2009, primarily from increased contract manufacturing revenues generated by Avid Bioservices, the company's wholly owned subsidiary, and increased revenues derived from the company's R&D contract with the federal government.Avid generated manufacturing revenues of $5,009,000 for the fourth quarter of FY 2009, compared to $751,000 for the comparable prior year quarter, while full year FY 2009 manufacturing revenues more than doubled to $12,963,000, up from $5,897,000 in FY 2008. The increase in Avid revenues reflects increased manufacturing services provided to third-party customers during the quarter and the full fiscal year. In addition to manufacturing revenues, during FY 2009 Peregrine generated revenues from services provided under its government contract with the U.S. Defense Threat Reduction Agency to evaluate bavituximab as a potential broad spectrum treatment for viral hemorrhagic fever infections. Government contract revenues were $2,683,000 for the fourth quarter of FY 2009 and $5,013,000 for the 2009 fiscal year. Peregrine's work under the DTRA contract began during FY 2009, so there are no comparable figures for FY 2008.Total costs and expenses in the fourth quarter of FY 2009 were $11,239,000, compared to $7,198,000 in the fourth quarter of FY 2008. Increased costs of contract manufacturing were directly driven by the increase in Avid revenues, while the increased research and development costs were associated with increased costs incurred under the government contract. The fourth quarter increase in selling, general, and administrative expenses was primarily due to a one-time charge associated with a legal settlement. Total costs and expenses for the 2009 fiscal year were $34,467,000, compared to $30,233,000 in FY 2008, an increase of 14%. Increased contract manufacturing costs directly related to the increase in Avid revenues accounted for most of the increase in total expenses. R&D expenses for FY 2009 were essentially flat compared to FY 2008, despite the fact that clinical and other development activities related to the bavituximab clinical program significantly increased. The company was able to offset costs associated with these increased R&D activities by re-focusing effort from earlier stage preclinical programs to its clinical development efforts. SG&A expenses slightly decreased two percent in FY 2009 compared to FY 2008. Peregrine reported a consolidated net loss of $3,609,000, or $0.02 per basic and diluted share, in the fourth quarter of FY 2009, compared to a consolidated net loss of $6,159,000, or $0.03 per basic and diluted share, for the comparable period in FY 2008, a decrease of 41%. The company reported a consolidated net loss of $16,524,000, or $0.07 per basic and diluted share for FY 2009, compared to a consolidated net loss of $23,176,000, or $0.10 per basic and diluted share for FY 2008, a decrease of 29%. 'This has been a significant year of accomplishment at Peregrine as we delivered on our commitment to significantly expand and advance our bavituximab Phase II clinical program, which is already yielding encouraging data, while nearly tripling revenues and reducing our net loss by nearly 30%,' said Steven W. King, president and CEO of Peregrine. 'These accomplishments have allowed us to build significant value in our oncology clinical pipeline, to grow the value of our contract manufacturing business and to realize immediate value from our bavituximab anti-viral technology platform through our DTRA government contract. These achievements have created considerable momentum that we expect to maintain throughout the coming year.'Mr. King added, 'We more than doubled our Avid contract manufacturing revenues and recorded more than $5 million in first-year revenues from a multi-year government contract to evaluate our bavituximab anti-viral platform for its broad spectrum potential to treat or prevent serious virus infections. At the same time, we advanced our bavituximab and Cotara clinical trials in FY 2009 while keeping R&D costs flat. These trials have already yielded very promising early results, and we are optimistic they will continue to yield positive results during the current fiscal year.' Mr. King continued, 'This year we also made important progress in raising the profile of all three of our clinical programs among investors, potential partners and the medical community, and as a result, the pace of our partnering efforts has accelerated. Among the most significant developments driving this increased interest was the release of our first clinical data indicating that bavituximab may be a valuable new option for treating cancer. In three separate Phase II trials in combination with chemotherapy, bavituximab demonstrated encouraging signs of efficacy in patients with advanced breast cancer and advanced lung cancer. All three trials surpassed the requisite efficacy criteria for expansion of patient enrollment, which is now well underway. These trials, along with our Phase I bavituximab cancer study that recently completed patient enrollment, are helping to set the stage for advancing bavituximab toward later-stage clinical trials. Planning for this exciting next phase for our bavituximab oncology program has already begun.'Mr. King added, 'This past year we also made significant advancements in our bavituximab and broader anti-PS anti-viral program, receiving high-profile international validation through the publication of data in the highly respected scientific journal Nature Medicine, which confirmed the anti-viral potential of bavituximab and our other anti-PS antibodies. We were also successful in completing contract negotiations with the DTRA, allowing us to expand the evaluation of our anti-PS antibodies as potential broad spectrum agents for the treatment or prevention of viral hemorrhagic fever virus infections. This contract directly or indirectly supports our bavituximab and other anti-PS technology programs and represents another significant validation for the anti-PS technology platform.'Mr. King continued, 'Our Cotara clinical program continues to advance with patient enrollment nearing completion in our dose confirmation and dosimetry study in patients with recurrent glioblastoma , and enrollment exceeds the halfway mark in our Phase II trial in relapsed GBM patients. We recently presented dosimetry study data at the Society of Nuclear Medicine 2009 Annual Meeting, further confirming that Cotara specifically localizes to brain tumors at high concentrations with minimal radiation exposure to other organs, reinforcing its potential as a possible new treatment for GBM.'At April 30, 2009, Peregrine had $10 million in cash and cash equivalents, compared to $15.1 million in cash and cash equivalents at April 30, 2008. After the close of the 2009 fiscal year, Peregrine raised approximately $6.9 million in gross proceeds from the sale of common stock from its existing shelf registration. The stock was sold in an 'At the Market' offering as defined in Rule 415 of the Securities Act. This stock sale involved no discounts or warrants and required only a modest commission be paid to the underwriter.Paul Lytle, chief financial officer of Peregrine, noted, 'Our 'At the Market' sales agreement has proven to be a very successful financing vehicle, allowing us to sell shares of common stock at market prices and to raise the full target amount of $7.5 million in new equity for the company at favorable terms. With the successful closing of this equity sale, Peregrine had met all the conditions to draw down the second $5 million tranche under our current loan agreement. However, we have opted not to draw down the additional debt at this time. Instead, we plan to rely on our other potential sources of capital and the projected revenues from Avid and our DTRA government contract, thereby avoiding the additional costs and future repayment of principal and interest associated with taking on additional debt. The original loan we closed last December has served its purpose by allowing us to continue our R&D programs during very tough economic conditions.'The company's FY 2009 Annual Report on Form 10-K to be filed today will include an audit opinion with a "going concern" qualification. The qualification is a statement in the audit opinion of Ernst & Young LLP, the company's independent registered public accounting firm, expressing substantial doubt, based upon Peregrine's current financial resources, as to whether the company can continue to meet its financial obligations beyond fiscal year 2010 without access to additional cash and cash equivalents. Nasdaq Marketplace Rule 4350 requires Nasdaq-listed companies to announce publicly through the news media the receipt of an audit opinion containing a "going concern" qualification. Mr. Lytle added, 'We believe Peregrine has sufficient financial resources to meet its obligations through at least FY 2010, based on a number of factors. These factors include our recent success in reinforcing the company's cash position by raising approximately $6.9 million in new equity capital in FY 2010, our projected cash-inflows from Avid manufacturing revenues and from our DTRA government contract, as well as our substantial progress in managing expenses and significantly reducing our cash burn rate. Nonetheless, there are potential uncertainties associated with these financial projections that required the company's independent registered public accounting firm to include a 'going concern' qualification in its audit opinion. We therefore expect this unqualified opinion with an explanatory paragraph to have a minimal impact on the company as we continue to advance our clinical programs and service our Avid customers.' Mr. Lytle concluded, 'Looking ahead, we must have the ability to internally support our clinical programs and the expansion of those programs based on the promising data we have already seen. We therefore plan to file a shelf registration statement today with the SEC and concurrently enter into an 'At the Market' sales agreement so we can provide the company with the best possible options as we look at supplementing our revenue streams with additional equity capital. As we get closer to starting later-stage trials, drug development becomes more expensive, but the potential return to our company and our shareholders is also much greater.'Mr. King concluded, 'We believe that the company's future has never looked brighter. With multiple Phase II cancer trials underway, we expect a steady flow of clinical data during the 2010 fiscal year. Our promising clinical data and the validation our technology is receiving as a result of our enhanced publication and presentation activities and our ramped-up outreach efforts have helped put Peregrine on the radar screen of many more thought leaders, potential partners and investors. With our clinical programs on track to generate additional data, and contract revenues from Avid and our DTRA program continuing to increase, we anticipate that FY 2010 could be a very positive year for Peregrine." The company's Annual Report on Form 10-K will be filed later today and will be available at the SEC's website at www.sec.org, or through the investor portion of Peregrine's website at www.peregrineinc.com.Operating Highlights Since the Start of Fiscal Year 2009Bavituximab Anti-Cancer ProgramPeregrine reported progress in all four ongoing trials in its bavituximab cancer program, including its three Phase II trials:Completed enrollment of the planned 46 patients in a Phase II trial evaluating bavituximab in combination with docetaxel in advanced breast cancer patients. As reported in an oral presentation at the 2009 ASCO Annual Meeting, 10 of 14, or 71% of evaluable patients in the initial cohort demonstrated an objective tumor response according to RECIST criteria. These data exceeded the pre-specified endpoint needed to expand the trial and compare favorably with historical data with chemotherapy alone. Recent analysis shows the median progression free survival of patients enrolled in the first part of the study was 7.4 months, a promising early result. Patient dosing and follow-up in this trial are continuing.Reported that in a Phase II trial evaluating bavituximab in combination with carboplatin and paclitaxel in advanced breast cancer patients, nine of 14, or 64% of evaluable patients in the initial cohort achieved an objective tumor response according to RECIST criteria. These data exceeded the pre-specified endpoint needed to expand the trial. Patient enrollment and dosing are underway in the expansion stage of the trial, which will enroll a total of 46 advanced breast cancer patients overall.Reported that in a Phase II trial evaluating bavituximab in combination with carboplatin and paclitaxel in non-small cell lung cancer patients with locally advanced or metastatic disease, 11 of 17, or almost 65% of evaluable patients in the initial cohort, achieved an objective tumor response according to RECIST criteria. These early results, which exceeded the pre-specified endpoint needed to expand the trial, compare very favorably with historical data with chemotherapy alone and are especially encouraging in this hard-to-treat cancer. Patient enrollment and dosing are continuing in the expansion stage of the trial, which will enroll a total of 49 NSCLC patients overall. Completed patient enrollment in a Phase I trial evaluating bavituximab as monotherapy in patients with advanced refractory cancers. At the 2009 ASCO Annual Meeting, study researchers reported that bavituximab had demonstrated a predictable pharmacokinetic profile and acceptable safety, and that a maximum tolerated dose was not reached, even at the highest planned dose level. Announced that the ASCO Research Foundation awarded one of its 2009 Career Development Awards to a researcher at the University of Texas Southwestern Medical Center for a study of the biologic effects of bavituximab and chemotherapy in patients with advanced lung cancer.Presented data from two studies at the AACR 2009 Annual Meeting providing further confirmation of the unique immunomodulatory mechanisms contributing to the anti-tumor activity of Peregrine's anti-PS antibody platform. Bavituximab Anti-Viral ProgramThe company continued to advance the bavituximab anti-viral program:Received major validation of the broad anti-viral potential of the company's anti-PS antibody platform with the publication of data in Nature Medicine showing that its PS-targeting drug bavituximab can cure lethal virus infections in animal disease models.Entered into a five-year contract potentially worth up to $44.4 million with the Department of Defense's Defense Threat Reduction Agency , and ramped up activities under this contract to assess bavituximab and other anti-PS antibodies for biodefense applications against viral hemorrhagic fevers. Continued to enroll and dose patients in an ongoing Phase I clinical trial of bavituximab in hepatitis C virus infected patients co-infected with HIV.Was awarded a U.S. patent that includes broad claims covering anti-viral applications of antibodies that directly bind to aminophospholipids, including PS.Reported that the company's anti-PS technology was positively highlighted in scientific sessions at the AIDS Vaccine 2008 conference in Cape Town, South Africa.Cotara Brain Cancer ProgramReported that patient enrollment in the Cotara dosing and dosimetry trial at U.S. brain cancer centers was nearing completion, and that patients in the initial two cohorts of the study have all either met or exceeded the expected median survival time of six months for recurrent glioblastoma multiforme patients.Presented data at the Society of Nuclear Medicine 2009 Annual Meeting showing that Cotara specifically localizes to brain tumors at high concentrations with minimal radiation exposure to other organs. This data confirms a key safety attribute of Cotara - its ability to precisely target tumors. Data showed that the concentration of Cotara in brain tumors was on average more than 300-fold higher than in normal organs. Reported that patient enrollment has exceeded the halfway mark in the Cotara Phase II trial in patients with relapsed GBM.Avid BioservicesAvid management gave scientific presentations at a number of industry meetings, including the 2009 BIO International Convention, highlighting the company's distinctive capabilities and experience.Avid expanded its biomanufacturing capabilities with the installation of two Thermo Scientific HyClone Single-Use Bioreactors, which further enhance Avid's ability to meet the growing demand for its cell culture production services.Signed a manufacturing supply agreement with Catalyst Biosciences to produce clinical-grade material for their candidate for the treatment of acute bleeding in hemophilia patients.Other DevelopmentsPeregrine settled a lawsuit with Cancer Therapeutics Laboratories . Under the terms of the agreement, CTL is transferring shares in Medibiotech Co., Inc. to Peregrine, giving Peregrine close to a 5% ownership stake in Medibiotech. Medibiotech is a Chinese company that has the exclusive rights in the People's Republic of China to develop and market a version of Peregrine's radiolabeled tumor necrosis therapy technology for the treatment of cancer. Peregrine will also make certain cash payments to CTL.In March 2009, Peregrine announced an agreement with Wm Smith & Co. to raise a target of $7.5 million from its existing shelf registration by selling new equity in an 'At the Market' offering as defined in Rule 415 of the Securities Act. The stock was sold at market prices between April and early June by Wm Smith & Co. to reach the targeted $7.5 million in new capital.Entered into a loan agreement for up to $10 million to finance ongoing clinical development efforts. Peregrine received an initial $5 million tranche and later declined an option for a second $5 million tranche.Received a letter from NASDAQ providing Peregrine with additional time to regain compliance with NASDAQ's $1.00 minimum bid price rule. Peregrine now has at least until October 26, 2009 to regain compliance. Received shareholder approval at the Annual Meeting of Stockholders held on October 21, 2008, for a proposal that provides the company's Board of Directors with discretionary authority to implement a reverse split of the issued and outstanding shares of Peregrine's common stock before the 2009 Annual Meeting.Conference CallThe company will host a conference call today, July 14, 2009 at 11:30 a.m. EDT/8:30 a.m. PDT to discuss its fiscal year 2009 financial results.To listen to a live broadcast of the call over the Internet or to review the archived call, please visit: www.peregrineinc.com. The webcast will be archived on Peregrine's website for approximately 30 days.To listen to the conference call via telephone, please call the following number approximately 10 minutes prior to the scheduled start time and request to join the Peregrine Pharmaceuticals call: 860-2442. A telephonic replay of the conference call will be available starting approximately one hour after the conclusion of the call through July 21, 2009 by calling 344-7529, passcode 431883#.About Peregrine PharmaceuticalsPeregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing three separate clinical programs in cancer and hepatitis C virus infection with its lead product candidates bavituximab and Cotara. Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. , which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to the risk that the company may experience delays in clinical trial patient enrollment, the results of future clinical trials may not correlate with the results from prior clinical and preclinical studies, the risk that the rate of objective tumor response for the expansion stages of the company's three Phase II trials will not be consistent with the objective tumor responses experienced in the first stage of the respective Phase II trials, the risk that the standard chemotherapy response rate will not be improved as a result of the combination therapy with the inclusion of bavituximab, the risk that the company will not be able to raise additional capital under its 'At the Market' sales agreement, the risk that Avid's revenue growth may slow or decline, the risk that Avid may experience technical difficulties in processing customer orders which could delay delivery of products to customers and receipt of payment, the risk that one or more existing Avid customers terminates its contract prior to completion, the risk that the company does not receive all of its funding under the DTRA contract, the risk that future protocol submissions may not be approved and the risk that the company may not be able to monetize any of its assets. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the Company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2009. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release. Contacts:[More...]

Jesup & Lamont Announces Presenting LifeTech Companies and Former FDA Commissioner at Annual Growth Stock & National Sales Conference

Mon, 13 Jul 2009 12:26:00 GMT

Jesup & Lamont, Inc., , a full-service boutique brokerage and investment banking firm serving retail and institutional clients, today announced the LifeTech Capital Group companies presenting at its 2009 Growth Stock & National Sales Conference to be held at the Waldorf Astoria Boca Beach Club on July 30th, 2009 in Boca Raton, Florida. In addition, former FDA Commissioner Dr. Lester M. Crawford D.V.M., Ph.D., will be the keynote speaker for the event.[More...]

BenchmarkJournal.Com Free Analyst Review for GAP, ATU, PPHM, MNKD, HLIT and COCO

Thu, 02 Jul 2009 14:16:00 GMT

Benchmark Journal brings independent company and sector research together, utilizing top financial advisors and investment tactics to provide you with a clear picture of investment opportunities.
Today we began research on GREAT ATLANTIC PAC (NYSE: GAP), Actuant Corp New (NYSE: ATU), Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), MannKind Corporation (NASDAQ: MNKD), Harmonic Inc. (NASDAQ: HLIT) and Corinthian Colleges Inc. (NASDAQ: COCO).
To view our research, sign up now and get started with your complimentary subscription.

[More...]

Peregrine Pharmaceuticals to Report Fiscal Year 2009 Financial Results

Thu, 02 Jul 2009 11:25:00 GMT

Peregrine Pharmaceuticals, Inc. today announced that it will release its fourth quarter and fiscal year 2009 financial results on July 14, 2009 at 7:00 a.m. EDT and will host a conference call and webcast to discuss the results at 11:30 a.m. EDT on the same day.[More...]

Peregrine Awarded European Patent for Innovative Labeling Technology Featured in New Study in The Journal of Nuclear Medicine

Wed, 01 Jul 2009 11:57:00 GMT

Peregrine Pharmaceuticals, Inc. today announced that it has been awarded a European patent for a novel device and methods for linking biological agents to labels for diagnostic and therapeutic applications. The technology, which is known as In-Line labeling, was developed for the production of radiolabeled anti-cancer antibodies, but is applicable to other agents as well. A study published today in the July 2009 issue of The Journal of Nuclear Medicine confirms that In-Line labeling can dramatically reduce the complexity and cost of producing radiolabeled cancer drugs. In-Line labeling is already being used for the production of Peregrine's radiolabeled antibody Cotara, currently in Phase II trials for the treatment of glioblastoma multiforme, a deadly form of brain cancer.[More...]

Peregrine Pharmaceuticals Completes Planned Patient Enrollment in Bavituximab Phase I Cancer Trial

Tue, 30 Jun 2009 12:57:00 GMT

- Completion of Phase I Paves Way for Expanding Bavituximab Cancer Program -[More...]

Form 4 PEREGRINE PHARMACEUTICAL For: Oct 21 Filed by: King F David (10K)

Fri, 23 Oct 2009 23:10:00 GMT

[More...]

Form 3 Shan Joseph For: Mar 12 (10K)

Fri, 13 Mar 2009 21:56:00 GMT

[More...]

Form 5 PEREGRINE PHARMACEUTICAL For: Apr 30 Filed by: POHL DAVID (10K)

Thu, 19 Jun 2008 22:55:00 GMT

[More...]